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Abstract
Background and Purpose: In animal models, von Willebrand factor (VWF) is involved in thrombus formation and
propagation of ischemic stroke. However, the pathophysiological relevance of this molecule in humans, and its potential
use as a biomarker for the risk and severity of ischemic stroke remains unclear. This study had two aims: to identify
predictors of altered VWF levels and to examine whether VWF levels differ between acute cerebrovascular events and
chronic cerebrovascular disease (CCD).
Methods: A case–control study was undertaken between 2010 and 2013 at our University clinic. In total, 116 patients with
acute ischemic stroke (AIS) or transitory ischemic attack (TIA), 117 patients with CCD, and 104 healthy volunteers (HV) were
included. Blood was taken at days 0, 1, and 3 in patients with AIS or TIA, and once in CCD patients and HV. VWF serum levels
were measured and correlated with demographic and clinical parameters by multivariate linear regression and ANOVA.
Results: Patients with CCD (158646%) had significantly higher VWF levels than HV (113636%, P,0.001), but lower levels
than AIS/TIA patients (200695%, P,0.001). Age, sex, and stroke severity influenced VWF levels (P,0.05).
Conclusions: VWF levels differed across disease subtypes and patient characteristics. Our study confirms increased VWF
levels as a risk factor for cerebrovascular disease and, moreover, suggests that it may represent a potential biomarker for
stroke severity, warranting further investigation.
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Background
Plasmatic coagulation and platelets are critically involved in
lesion development after ischemic stroke (IS) [1,2]; however, their
specific roles and their interplay with endothelial cells or other
resident brain cells long remained elusive. Recently, the develop-
ment of transgenic mouse models and specific antibodies has
enabled the discovery of distinct pathways in pathological
thrombus formation in animal models of IS [2,3]. Von Willebrand
factor (VWF) plays a key pathophysiologic role in arterial
thrombus formation in the brain and heart [4,5]. VWF is a large,
multimeric glycoprotein that is exclusively synthesized in endo-
thelial cells and megakaryocytes and circulates as multimers of
varying size (up to 20 000 kDa). A disintegrin and metalloprotease
with thrombospondin Type 1 repeats 13 (ADAMTS13) digests
ultralarge VWF into smaller and less reactive molecules [4]. VWF
mediates loose adhesion of platelets to the vascular wall and
therefore, the earliest step of thrombus formation through binding
to glycoprotein (Gp)Ib expressed on platelets [2,6].
Research to date has shown that in vivo blockade of the GpIb–
VWF axis resulted in the elimination of arterial thrombus
formation in primates [7], restored vessel patency by dissolving
platelet aggregates [8], and led to significantly reduced infarct
volumes and better functional outcome in rodent stroke models
[4–6] and larger animals [9]. Furthermore, targeting GpIb and its
major ligand VWF has provided beneficial effects in IS models
without a concomitant increase in bleeding complications, which
led to the unique and intriguing concept of a potential ‘‘bleeding-
free’’ antithrombotic approach [2]. Thus, targeting VWF-mediat-
ed platelet adhesion and activation is now considered as a potential
target for stroke prevention and acute stroke treatment. However,
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a conservative view is warranted given that attempts to translate
the findings with this approach from animal stroke studies to
humans has yielded disappointing results [10].
Despite increasing evidence of a causal association between
VWF levels and acute stroke risk in humans [11,12] many
questions remain unanswered. For instance, the processes involved
in the regulation of VWF expression during ischemic stroke and
the specific contribution of VWF to the preceding pathophysio-
logic events await clarification. Also, the relationship of VWF
levels to other parameters, such as genetic polymorphisms [13]
and demographic features [14], is not well understood. Addition-
ally, only limited data exist on the regulation of VWF in patients
with chronic cerebrovascular disease (CCD) [15–17].
The aim of the study was to identify demographic and clinical
predictors of VWF serum levels and to evaluate whether VWF
levels differ between acute cerebrovascular events and chronic
cerebrovascular disease (CCD).
Methods
Data Collection
For addressing these objectives, a case-control study was
performed. As cases, patients with acute (acute ischemic stroke
Table 1. Baseline characteristics of acute ischemic stroke (AIS)/transitory ischemic attack (TIA) patients.
Characteristic Value (n=116)
Age, years 70612
Sex, n (%)
Male 62 (53)
Female 54 (47)
Modality, n (%)
AIS 67 (58)
TIA 49 (42)
TOAST criteria, n (%)
Cardioembolism 70 (60)
Large-artery atherosclerosis 4 (3)
Small-vessel occlusion 12 (10)
Other determined or undetermined etiology 30 (26)
Thrombolysis, n (%) 34 (29)
Comorbidities, n (%)
Hypertension 105 (92)
Diabetes mellitus 41 (35)
Hyperlipidemia 80 (69)
Renal failure 10 (9)
Atrial fibrillation 37 (32)
Persistent foramen ovale 28 (24)
Heart failure 5 (4)
Coronary artery disease 8 (7)
Family history of stroke 11 (10)
Smoking, n (%) 18 (16)
Platelet inhibitor before blood withdrawal, n (%) 87 (75)
Anticoagulation before blood withdrawal, n (%) 8 (7)
Lipid-lowering drug before blood withdrawal, n (%) 36 (31)
National Institutes of Health Stroke Scale at admission 4.866.0
Barthel Index at admission 74630
Body mass index, kg/m2 2765
HbA1c, mmol/mol hemoglobin 46613
Lipid profile, mmol/L
Total cholesterol 202652
Low-density lipoprotein 121645
High-density lipoprotein 51615
Triglycerides 1576153
Duration between symptom onset and blood withdrawal, h 1467
HbA1c, glycated hemoglobin; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
doi:10.1371/journal.pone.0099851.t001
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[AIS], transitory ischemic attack [TIA]) and CCD were recruited.
As controls, healthy volunteers (HV) from the local population
were chosen. The participants were recruited at the Stroke Unit
(in-patients diagnosed with TIA or AIS), at the out-patient clinic
for CCD, or after a call for HV by means of posters at the
Neurology Department, University Hospital of Wu¨rzburg, Ger-
many, between September 2010 and January 2013. Inclusion
criteria included blood withdrawal within 24 h after symptom
onset in AIS (defined as acute ischemic lesion on brain imaging)
and TIA (no acute lesion) patients, presentation with extra- and/or
intracranial stenosis of the large cerebral arteries with (n = 66) or
without (n = 51) history of AIS or TIA for the CCD group and no
history of stroke, myocardial infarction, or peripheral arterial
disease for the HV group. Exclusion criteria were hemorrhagic
stroke, age,18 years, and known platelet dysfunction or plasmatic
coagulation disorders based on a detailed medical history and
collection of routine coagulation parameters. Overall, 116 patients
with AIS or TIA, 117 patients with CCD, and 104 HV fulfilled the
inclusion criteria and took part in the study.
In the patients with AIS or TIA, TOAST (Trial of Org 10172 in
Acute Stroke Treatment) criteria [18] were applied in an adapted
form: (1) cardioembolism; (2) large-artery atherosclerosis: (3) small-
vessel occlusion; or (4) other determined or undetermined etiology.
The National Institute of Health Stroke Scale (NIHSS) [19] and
Barthel Index score [20] were calculated at patient admission. The
latency between symptom onset and blood withdrawal, platelet
inhibitor pretreatment, and modality of acute stroke therapy
(thrombolysis vs. no thrombolysis) were registered.
Blood Collection and Measurements
Blood was collected on day 0, 1, and 3 in the patients with acute
cerebrovascular disease, and once in CCD patients and HV
between 08.00 and 12.00 hours from an antecubital vein using a
21-gauge butterfly needle. Pre-analytic preparations for blood
collection followed a specific standard operating procedure. Only
non-hemolyzed blood samples were analysed. VWF, differential
hematology parameters, and C-reactive protein (CRP) were
analysed at the Division of Laboratory Medicine of the University
Hospital Wu¨rzburg.
Statistical Analysis
Continuous variables are expressed as mean with standard
deviation or median with interquartile range, as appropriate.
Categorical variables are expressed as percentages. The associa-
tion between VWF concentrations and a range of demographic
and clinical characteristics was explored: age, sex, neurological
scales, disease modality (TIA or AIS), TOAST criteria, duration
between symptom onset and blood withdrawal, NIHSS, Barthel
Index, treatment modality (intravenous thrombolysis or not), and
intake of platelet inhibitors in the days before blood withdrawal. P
values for comparisons across groups of clinical and demographic
characteristics were derived from analysis of variance (ANOVA),
and the chi-square test, as appropriate. In order to identify
potential predictors of VWF levels, a linear regression model was
used that included all variables without co-linearity in a
multivariate model adjusting for age and sex. Using this model,
coefficients and the corresponding 95% confidence intervals (CIs)
were estimated. VWF biomarker levels were compared between
the different patients groups (AIS/TIA in-patients, CCD out-
patients, or HV). Distribution was analyzed using the Kolmo-
gorov–Smirnov test. Levels of VWF were assumed to take a
normal distribution and were compared using ANOVA with a
Bonferroni post-hoc test and additionally adjusted for age and sex.
All reported P values are two-sided and a P value,0.05 was
considered statistically significant. Analyses were performed using
SPSS Version 21 and SAS software version 9.1 (SAS Institute Inc.,
Cary, NC).
Ethics
Informed written consent was obtained from all participants.
The study protocol was approved by the ethics committee of the
medical faculty of the University of Wu¨rzburg, Germany
(reference number 65/2010). Study participation had no influence
on treatment and patient care.
Results
Descriptive Analysis of the Patients with an Acute
Cerebrovascular Event
A total of 116 patients with AIS/TIA were included in this
study. The mean age of these patients was 70612 years; 53% of
whom were male. The baseline clinical severity measured with
NIHSS and Barthel Index was 4.866.0 and 74630, respectively.
More than half of the patients had an AIS (58%). A detailed
descriptive analysis of the characteristics of the patients with acute
cerebrovascular event is given in Table 1.
Comparison of VWF Levels in AIS/TIA Patients, CCD
Patients, and HV
VWF levels by patient subtype with acute cerebrovascular
events (AIS or TIA), or chronic cerebrovascular disorders (CCD),
were compared with the levels of HV. VWF levels showed
significant differences between the three groups (AIS/TIA:
200695%; CCD: 158646%; HV: 113636%) (Figure 1). Both
patient subtypes had significantly higher levels than HV, AIS and
TIA patients even higher than CCD patients (all P,0.001). After
adjustment for age and sex, highly significant results remained (P,
0.001) (data not shown).
Figure 1. von Willebrand factor (VWF) levels in acute ischemic
stroke (AIS)/transitory ischemic attack (TIA), chronic cerebro-
vascular disease (CCD), and healthy volunteers (HV). The VWF
levels are depicted in box-and-whisker plots indicating the first and
third quartiles as well as the 1.5 interquartile range (IQR, Tukey plot).
Outliers outside 1.5 IQR are visualized by single dots. VWF levels
showed significant differences between the three groups. Analysis of
variance with Bonferroni post hoc test, ***P,0.001. d0 = day 0.
doi:10.1371/journal.pone.0099851.g001
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Relationship between VWF Levels and Key Demographic
and Clinical Parameters in Patients with an Acute
Cerebrovascular Event
The potential relationship between VWF levels and standard
laboratory parameters such as CRP or blood count was evaluated.
VWF levels were significantly correlated with CRP (r = 0.30,
P= 0.001) and different leukocyte subsets (leukocyte count:
r = 0.29, P= 0.002; neutrophil count: r = 0.36, P,0.001; lympho-
cyte count: r =20.28, P= 0.002; monocyte count: r = 0.20,
P= 0.03) (data not shown).
The association between VWF levels and key demographic and
clinical characteristics was assessed in a univariate analysis
(Table 2). Age (P= 0.001), disease modality (TIA vs. AIS)
(P= 0.01), and clinical severity (NIHSS: P= 0.001; Barthel Index:
P,0.001) showed a significant association with serum VWF levels.
VWF levels increased with patient age and clinical severity, while
AIS patients had higher VWF levels than TIA patients.
A multivariate analysis of all variables was performed using a
linear regression model (Table 3). Three parameters: NIHSS.15
points, intake of platelet inhibitors before blood withdrawal, and
CRP at admission, were identified as independent predictors of
VWF levels. The time point of blood withdrawal (days 0, 1 and 3)
did not influence VWF levels (P= 0.99) (data not shown).
Table 2. Predictors of von Willebrand factor (VWF) levels in acute ischemic stroke (AIS)/transitory ischemic attack (TIA) patients by
univariate analysis.
VWF (%) P value
Sex, n
Male 189687
Female 2126103 0.30
Age, years
,55 157644
55–64 2076117
65–74 188676
75–84 207672
.84 2536154 0.001
Disease modality
AIS 2196101
TIA 173680 0.01
Modified TOAST criteria
Cardioembolism 200687
Large-artery atherosclerosis 2756131
Small-vessel occlusion 170679
Other determined or undetermined etiology 2016111 0.30
Duration between symptom onset and blood withdrawal, h
,5 2336134
5–12 184689
12–24 1906215 0.11
National Institutes of Health Stroke Scale
0–4 179671
5–9 2126102
10–15 220655
.15 2996182 0.001
Barthel Index
0–30 2866146
35–70 182661
.70 166652 ,0.001
Thrombolysis
Yes 2236101
No 190691 0.09
Platelet inhibitor before blood withdrawal
Yes 189683
No 2186111 0.11
TOAST = Trial of Org 10172 in Acute Stroke Treatment.
doi:10.1371/journal.pone.0099851.t002
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Discussion
This study shows that VWF serum levels are significantly
increased in both acute and chronic cerebrovascular disorders
compared with healthy persons. Furthermore, we identified
important demographic and clinical predictors of VWF levels in
patients with acute IS or transitory ischemic attack.
It is known that VWF is a risk factor for coronary heart disease
[21]. Despite a few studies that could not find an association
between VWF levels and stroke risk or increased coagulability
[22,23], the vast majority of prospective studies point towards high
VWF levels as risk factor also for AIS [12,24–28]. Our findings
support this hypothesis by showing that VWF levels are higher in
patients with an acute cerebrovascular event or CCD than in
healthy individuals. Importantly, stroke severity (NIHSS.15
points), CRP levels at admission, and the intake of platelet
inhibitors in the days before blood withdrawal each independently
predicted VWF levels.
Previous case–control studies demonstrated increased VWF
levels in patients with IS [11,29–31]. While Hanson and co-
workers described that VWF levels differed between etiologic
subtypes of IS, we found no such association [29]. Our finding of
an association of CRP and VWF levels in the acute phase after IS
highlights the role of VWF as an acute-phase reactant associated
with inflammation [32] and, in particular, with thrombo-
inflammation in IS [4,33,34]. The term ‘‘thrombo-inflammation’’
describes the interaction of thrombotic (e.g. coagulation factors,
platelets) and inflammatory (e.g. immune cells) circuits operating
at the ischemic neurovascular unit and has recently been identified
as key mechanism of stroke occurrence and propagation at least in
rodents [33,34].
Elevated levels of VWF in patients with chronic cerebrovascular
disease compared with healthy controls presented herein is similar
to the findings of a previous study, which showed that subjects with
carotid plaques have elevated VWF levels [35]. In addition, a
recent report shows that atherosclerotic geometries exacerbate
pathological thrombus formation post-stenosis in a VWF-depen-
dent manner [36]. However, findings from another investigation
suggest that the additional explanatory power of VWF (on top of
the traditional risk factors, such as hypertension and diabetes) is
comparatively low in patients with carotid atherosclerosis [37].
Growing evidence indicates that demographic and clinical
parameters as well as therapeutic interventions can influence VWF
levels [16,17], but the relevance of these variables on VWF
regulation in different disease settings is unclear. Our findings, and
those of other researchers, underline the complexity of associations
with VWF levels. On the one hand, a high VWF level at admission
is indicated as a marker of severe IS; on the other hand, VWF level
is influenced by a variety of other variables (e.g. ABO blood group
[38–41], existence and composition of carotid plaques [15,16])
which complicates its interpretation. Only recently, it has been
shown that extracellular sodium levels within the high physiolog-
ical range can raise VWF levels thereby increasing the risk of
pathological thrombosis [42].
Our findings raise important considerations for clinical practice.
It may be hypothesized that VWF level could represent a potential
biomarker of stroke risk and stroke severity. Yet, the proactive
screening of VWF levels on a regular basis to assess the risk of
thromboembolic disease in individual patients has still not been
recommended by medical societies [4]. This may be due to the
lack of standardized test systems [4], or the confounding of
measurements by the current lack of understanding of factors that
influence VWF levels [13,14] – which would impede the
interpretation of findings and the prediction of the corresponding
cerebrovascular risk.
In addition, VWF levels could perhaps provide a means to
screen patients for specific treatment approaches. In various stroke
models, blocking VWF by monoclonal antibodies has been shown
Table 3. Predictors of von Willebrand factor levels in acute ischemic stroke (AIS)/transitory ischemic attack (TIA) patientsby
multivariate analysis.
Coefficient 95% confidence interval P value
Sex
Male Reference
Female Age, years 4.12615.75 227.13 to 35.37 0.79
,55 Reference
55–64 37.28627.04 216.35 to 90.92 0.17
65–74 24.43625.22 225.62 to 74.47 0.34
75–84 39.70626.68 213.23 to 92.64 0.14
.84 37.83633.84 229.30 to 104.97 0.27
Disease modality 22.09617.47 212.58 to 56.76 0.21
National Institutes of Health Stroke Scale
0–4 Reference
5–9 11.20623.52 235.47 to 57.86 0.64
10–15 36.75627.77 218.35 to 91.86 0.19
.15 71.13632.47 6.72 to 135.55 0.03
Thrombolysis 20.68620.35 241.06 to 39.69 0.97
Platelet inhibitor before blood taking 241.09616.66 274.13 to 28.05 0.02
C-reactive protein at admission, mg/dl 8.9162.25 4.44 to 13.37 ,0.001
Neutrophils at admission, n*1000/ml 1.0363.85 26.61 to 8.67 0.79
doi:10.1371/journal.pone.0099851.t003
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to provide an impressive protective effect [5,9]. Assuming that
patients with high VWF levels would benefit most from such a
potential future pharmacological anti-VWF therapy, it could be
important to identify those patients. Based on our results, patients
with severe IS without previous intake of platelet inhibitors show
the highest levels of VWF and could possibly be the patient
subgroup most suited to a targeted anti-VWF therapy. Of course,
pharmacological targeting of VWF presents many challenges, and
might be less reliable than blocking other more ‘‘inert’’ molecules
of thrombus formation.
Our study has several limitations. Because of the case–control
study design, blood withdrawal took place post-cerebrovascular
event, which might lead to a reverse causation. However, the
increase in VWF levels in patients with AIS persisted over 3 days.
This suggests that elevated VWF levels were not due to early and
transient activation of the cerebral endothelium. Rather, a pre-
existing rise in VWF levels, i.e. before the occurrence of the
ischemic event, might be postulated. Nevertheless, it should be
emphasized that this study describes the degree and significance of
associations between VWF levels and demographic/clinical
parameters, but does not assign causality. To overcome this
limitation, prospective clinical trials should follow this case–control
study. Furthermore, for ethical reasons, we could not recruit
patients who were unable to give informed consent. Thus, patients
with very large strokes and/or aphasia might be under-represented
in our study. Further limitations include the relatively high
proportion of TIA patients (42%) for which a non-vascular origin
of symptoms cannot be entirely excluded, and treatment with
anticoagulants in 7% of AIS/TIA patients which might interfere
with the regulation of VWF levels.
Conclusion
In summary, we have demonstrated in this pilot study that an
important potential biomarker and promising target for future
therapeutic approaches, VWF, is differentially regulated in
patients with acute and chronic cerebrovascular diseases. The
ability to distinguish patient subtypes, or those at risk of an event,
on the basis of VWF levels is a tempting approach that may enable
better diagnosis or more targeted therapy in the future. In
addition, this study adds to our knowledge of the factors that can
influence VWF levels in a given patient. Nevertheless, prospective
clinical trials are necessary to reproduce these results and to
overcome the limitations that accompany retrospective study
designs.
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